Koninklijke Philips (NYSE:PHG) Rating Increased to Neutral at UBS Group

Koninklijke Philips (NYSE:PHG) was upgraded by research analysts at UBS Group from a “sell” rating to a “neutral” rating in a report released on Tuesday, MarketBeat reports.

Other research analysts have also issued reports about the stock. StockNews.com raised shares of Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. JPMorgan Chase & Co. raised shares of Koninklijke Philips from an “underweight” rating to a “neutral” rating in a research note on Tuesday. Finally, BNP Paribas cut shares of Koninklijke Philips from an “outperform” rating to an “underperform” rating in a research report on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $19.00.

Koninklijke Philips Price Performance

PHG stock opened at $26.78 on Tuesday. The company has a market capitalization of $24.86 billion, a PE ratio of -27.89, a price-to-earnings-growth ratio of 1.38 and a beta of 0.88. The company’s fifty day moving average price is $20.83 and its 200-day moving average price is $21.09. Koninklijke Philips has a one year low of $17.75 and a one year high of $29.44. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.78 and a current ratio of 1.20.

Koninklijke Philips (NYSE:PHG) last released its quarterly earnings data on Monday, January 29th. The technology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The business had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.47 billion. Koninklijke Philips had a positive return on equity of 9.82% and a negative net margin of 4.41%. On average, equities analysts anticipate that Koninklijke Philips will post 1.53 EPS for the current fiscal year.

Hedge Funds Weigh In On Koninklijke Philips

Several large investors have recently modified their holdings of PHG. Principal Securities Inc. bought a new stake in Koninklijke Philips in the fourth quarter worth $27,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Koninklijke Philips during the 1st quarter worth about $40,000. Fifth Third Bancorp grew its holdings in Koninklijke Philips by 34.4% during the 1st quarter. Fifth Third Bancorp now owns 3,008 shares of the technology company’s stock valued at $60,000 after purchasing an additional 770 shares during the last quarter. Allworth Financial LP raised its position in Koninklijke Philips by 113.3% in the 3rd quarter. Allworth Financial LP now owns 3,242 shares of the technology company’s stock worth $65,000 after purchasing an additional 1,722 shares during the period. Finally, Spire Wealth Management lifted its stake in Koninklijke Philips by 127.2% in the third quarter. Spire Wealth Management now owns 3,446 shares of the technology company’s stock worth $69,000 after purchasing an additional 1,929 shares during the last quarter. Institutional investors own 13.67% of the company’s stock.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.